{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:32:21Z","timestamp":1778859141709,"version":"3.51.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00345-021-03632-6","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T13:04:14Z","timestamp":1613999054000},"page":"2831-2841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comorbidity and frailty assessment in renal cell carcinoma patients"],"prefix":"10.1007","volume":"39","author":[{"given":"Jean","family":"Courcier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"De La Taille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Lassau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-6520","authenticated-orcid":false,"given":"Alexandre","family":"Ingels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"3632_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"3632_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00345-010-0555-1","volume":"28","author":"S Weikert","year":"2010","unstructured":"Weikert S, Ljungberg B (2010) Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 28:247\u2013252. https:\/\/doi.org\/10.1007\/s00345-010-0555-1","journal-title":"World J Urol"},{"key":"3632_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC et al (2020) Epidemiology of renal cell carcinoma. World J Oncol 11:79\u201387. https:\/\/doi.org\/10.14740\/wjon1279","journal-title":"World J Oncol"},{"key":"3632_CR4","unstructured":"SEER*Explorer Application. https:\/\/seer.cancer.gov\/explorer\/application.html?site=630&data_type=4&graph_type=5&compareBy=sex&chk_sex_1=1&series=9&race=1&age_range=1&stage=101&advopt_precision=1#tableWrap. Accessed 9 Jan 2021"},{"key":"3632_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0022-5347(17)68620-8","volume":"64","author":"V Vermooten","year":"1950","unstructured":"Vermooten V (1950) Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma. J Urol 64:200\u2013208. https:\/\/doi.org\/10.1016\/s0022-5347(17)68620-8","journal-title":"J Urol"},{"key":"3632_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.eururo.2011.03.030","volume":"60","author":"MAS Jewett","year":"2011","unstructured":"Jewett MAS, Mattar K, Basiuk J et al (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. EurUrol 60:39\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2011.03.030","journal-title":"EurUrol"},{"key":"3632_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.016","author":"G Curigliano","year":"2020","unstructured":"Curigliano G (2020) Recent eUpdate on cabozantinib and nivolumab for first-line clear cell renal cancer to the ESMO Clinical Practice Guidelines on Renal Cell Carcinoma. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.016","journal-title":"Ann Oncol"},{"key":"3632_CR8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393:2404\u20132415. https:\/\/doi.org\/10.1016\/S0140-6736(19)30723-8","journal-title":"Lancet"},{"key":"3632_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30436-8","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(20)30436-8","journal-title":"Lancet Oncol"},{"key":"3632_CR10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Motzer RJ, Rini BI et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31:1030\u20131039. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.010","journal-title":"Ann Oncol"},{"key":"3632_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"3632_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y et al (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. EurUrol 75:799\u2013810. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.011","journal-title":"EurUrol"},{"key":"3632_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0022-5347(05)00148-5","volume":"175","author":"SN Chawla","year":"2006","unstructured":"Chawla SN, Crispen PL, Hanlon AL et al (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175:425\u2013431. https:\/\/doi.org\/10.1016\/S0022-5347(05)00148-5","journal-title":"J Urol"},{"key":"3632_CR14","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1097\/01.ju.0000095475.12515.5e","volume":"170","author":"I Frank","year":"2003","unstructured":"Frank I, Blute ML, Cheville JC et al (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170:2217\u20132220. https:\/\/doi.org\/10.1097\/01.ju.0000095475.12515.5e","journal-title":"J Urol"},{"key":"3632_CR15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/jnci\/djj362","volume":"98","author":"JM Hollingsworth","year":"2006","unstructured":"Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98:1331\u20131334. https:\/\/doi.org\/10.1093\/jnci\/djj362","journal-title":"J Natl Cancer Inst"},{"key":"3632_CR16","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/cncr.25184","volume":"116","author":"BR Lane","year":"2010","unstructured":"Lane BR, Abouassaly R, Gao T et al (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116:3119\u20133126. https:\/\/doi.org\/10.1002\/cncr.25184","journal-title":"Cancer"},{"key":"3632_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cncr.26369","volume":"118","author":"MC Smaldone","year":"2012","unstructured":"Smaldone MC, Kutikov A, Egleston BL et al (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118:997\u20131006. https:\/\/doi.org\/10.1002\/cncr.26369","journal-title":"Cancer"},{"key":"3632_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.eururo.2020.06.053","volume":"78","author":"A Finelli","year":"2020","unstructured":"Finelli A, Cheung DC, Al-Matar A et al (2020) Small renal mass surveillance: histology-specific growth rates in a biopsy-characterized cohort. EurUrol 78:460\u2013467. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.053","journal-title":"EurUrol"},{"key":"3632_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.juro.2014.03.038","volume":"192","author":"R Mehrazin","year":"2014","unstructured":"Mehrazin R, Smaldone MC, Kutikov A et al (2014) Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. J Urol 192:659\u2013664. https:\/\/doi.org\/10.1016\/j.juro.2014.03.038","journal-title":"J Urol"},{"key":"3632_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.euf.2017.11.005","volume":"3","author":"DC Cheung","year":"2017","unstructured":"Cheung DC, Finelli A (2017) Active surveillance in small renal masses in the elderly: a literature review. EurUrol Focus 3:340\u2013351. https:\/\/doi.org\/10.1016\/j.euf.2017.11.005","journal-title":"EurUrol Focus"},{"key":"3632_CR21","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.juro.2009.12.101","volume":"183","author":"WT Lowrance","year":"2010","unstructured":"Lowrance WT, Yee DS, Savage C et al (2010) Complications after radical and partial nephrectomy as a function of age. J Urol 183:1725\u20131730. https:\/\/doi.org\/10.1016\/j.juro.2009.12.101","journal-title":"J Urol"},{"key":"3632_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/RRU.S220221","volume":"11","author":"W Sirithanaphol","year":"2019","unstructured":"Sirithanaphol W, Pachirat K, Rompsaithong U et al (2019) Perioperative outcomes in elderly patients undergoing nephrectomy for renal cell carcinoma. Res Rep Urol 11:195\u2013199. https:\/\/doi.org\/10.2147\/RRU.S220221","journal-title":"Res Rep Urol"},{"key":"3632_CR23","unstructured":"ASA Physical Status Classification System. https:\/\/www.asahq.org\/standards-and-guidelines\/asa-physical-status-classification-system. Accessed 3 Nov 2020"},{"key":"3632_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.eururo.2016.08.060","volume":"71","author":"MC Mir","year":"2017","unstructured":"Mir MC, Derweesh I, Porpiglia F et al (2017) Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. EurUrol 71:606\u2013617. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.060","journal-title":"EurUrol"},{"key":"3632_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.eururo.2006.11.013","volume":"51","author":"H Van Poppel","year":"2007","unstructured":"Van Poppel H, Da Pozzo L, Albrecht W et al (2007) A prospective randomized EORTC Intergroup Phase 3 Study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. EurUrol 51:1606\u20131615. https:\/\/doi.org\/10.1016\/j.eururo.2006.11.013","journal-title":"EurUrol"},{"key":"3632_CR26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.urology.2014.01.050","volume":"83","author":"A Becker","year":"2014","unstructured":"Becker A, Ravi P, Roghmann F et al (2014) Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. Urology 83:1285\u20131293. https:\/\/doi.org\/10.1016\/j.urology.2014.01.050","journal-title":"Urology"},{"key":"3632_CR27","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.m146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J GerontolABiolSci Med Sci 56:M146-156. https:\/\/doi.org\/10.1093\/gerona\/56.3.m146","journal-title":"J GerontolABiolSci Med Sci"},{"key":"3632_CR28","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/HJH.0000000000001286","volume":"35","author":"K Hidayat","year":"2017","unstructured":"Hidayat K, Du X, Zou S-Y, Shi B-M (2017) Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens 35:1333\u20131344. https:\/\/doi.org\/10.1097\/HJH.0000000000001286","journal-title":"J Hypertens"},{"key":"3632_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MOU.0000000000000454","volume":"28","author":"R Tahbaz","year":"2018","unstructured":"Tahbaz R, Schmid M, Merseburger AS (2018) Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. CurrOpinUrol 28:62\u201379. https:\/\/doi.org\/10.1097\/MOU.0000000000000454","journal-title":"CurrOpinUrol"},{"key":"3632_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.urolonc.2018.12.008","volume":"37","author":"O Al-Bayati","year":"2019","unstructured":"Al-Bayati O, Hasan A, Pruthi D et al (2019) Systematic review of modifiable risk factors for kidney cancer. UrolOncol 37:359\u2013371. https:\/\/doi.org\/10.1016\/j.urolonc.2018.12.008","journal-title":"UrolOncol"},{"key":"3632_CR31","doi-asserted-by":"publisher","first-page":"13347","DOI":"10.18632\/oncotarget.3749","volume":"6","author":"X Xu","year":"2015","unstructured":"Xu X, Zhu Y, Zheng X, Xie L (2015) Does beer, wine or liquor consumption correlate with the risk of renal cell carcinoma? A dose-response meta-analysis of prospective cohort studies. Oncotarget 6:13347\u201313358. https:\/\/doi.org\/10.18632\/oncotarget.3749","journal-title":"Oncotarget"},{"key":"3632_CR32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/ijc.28093","volume":"134","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK, Je Y, Cho E (2014) Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer 134:384\u2013396. https:\/\/doi.org\/10.1002\/ijc.28093","journal-title":"Int J Cancer"},{"key":"3632_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A et al (2019) Epidemiology of renal cell carcinoma. EurUrol 75:74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036","journal-title":"EurUrol"},{"key":"3632_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/1047-2797(91)90005-W","volume":"1","author":"LP Fried","year":"1991","unstructured":"Fried LP, Borhani NO, Enright P et al (1991) The cardiovascular health study: design and rationale. Ann Epidemiol 1:263\u2013276. https:\/\/doi.org\/10.1016\/1047-2797(91)90005-W","journal-title":"Ann Epidemiol"},{"key":"3632_CR35","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166\u20132172. https:\/\/doi.org\/10.1093\/annonc\/mdr587","journal-title":"Ann Oncol"},{"key":"3632_CR36","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J ClinOncol 32:2595\u20132603. https:\/\/doi.org\/10.1200\/JCO.2013.54.8347","journal-title":"J ClinOncol"},{"key":"3632_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","volume":"32","author":"C Kenis","year":"2014","unstructured":"Kenis C, Decoster L, Van Puyvelde K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J ClinOncol 32:19\u201326. https:\/\/doi.org\/10.1200\/JCO.2013.51.1345","journal-title":"J ClinOncol"},{"key":"3632_CR38","doi-asserted-by":"publisher","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","volume":"9","author":"P Soubeyran","year":"2014","unstructured":"Soubeyran P, Bellera C, Goyard J et al (2014) Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One 9:e115060. https:\/\/doi.org\/10.1371\/journal.pone.0115060","journal-title":"PLoS One"},{"key":"3632_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"3632_CR40","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J ClinEpidemiol 47:1245\u20131251. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5","journal-title":"J ClinEpidemiol"},{"key":"3632_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00432-019-03042-7","volume":"146","author":"HW Kang","year":"2020","unstructured":"The KORCC (KOrean Renal Cell Carcinoma) Group, Kang HW, Kim SM et al (2020) The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. J Cancer Res ClinOncol 146:187\u2013196. https:\/\/doi.org\/10.1007\/s00432-019-03042-7","journal-title":"J Cancer Res ClinOncol"},{"key":"3632_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/JCO.2009.22.4816","volume":"28","author":"A Kutikov","year":"2010","unstructured":"Kutikov A, Egleston BL, Wong Y-N, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J ClinOncol Off J Am SocClinOncol 28:311\u2013317. https:\/\/doi.org\/10.1200\/JCO.2009.22.4816","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"key":"3632_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"key":"3632_CR44","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.2147\/CMAR.S208839","volume":"11","author":"X Hu","year":"2019","unstructured":"Hu X, Wang Y, Yang W-X et al (2019) Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis. Cancer Manag Res 11:6163\u20136173. https:\/\/doi.org\/10.2147\/CMAR.S208839","journal-title":"Cancer Manag Res"},{"key":"3632_CR45","doi-asserted-by":"publisher","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B, Porta C, Schmidinger M et al (2016) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann OncolOff J EurSoc Med Oncol 27:v58\u2013v68. https:\/\/doi.org\/10.1093\/annonc\/mdw328","journal-title":"Ann OncolOff J EurSoc Med Oncol"},{"key":"3632_CR46","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","volume":"17","author":"BI Rini","year":"2016","unstructured":"Rini BI, Dorff TB, Elson P et al (2016) Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 17:1317\u20131324. https:\/\/doi.org\/10.1016\/S1470-2045(16)30196-6","journal-title":"Lancet Oncol"},{"key":"3632_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.urolonc.2007.10.017","volume":"27","author":"AS Wong","year":"2009","unstructured":"Wong AS, Chong K-T, Heng C-T et al (2009) Debulking nephrectomy followed by a \u201cwatch and wait\u201d approach in metastatic renal cell carcinoma. UrolOncol 27:149\u2013154. https:\/\/doi.org\/10.1016\/j.urolonc.2007.10.017","journal-title":"UrolOncol"},{"key":"3632_CR48","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1200\/JCO.2019.37.15_suppl.4516","volume":"37","author":"I Kushnir","year":"2019","unstructured":"Kushnir I, Basappa NS, Ghosh S et al (2019) Active surveillance in metastatic renal cell carcinoma (mRCC): results from the Canadian Kidney Cancer information system (CKCis). J ClinOncol 37:4516\u20134516. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4516","journal-title":"J ClinOncol"},{"key":"3632_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.21037\/atm.2019.01.08","volume":"7","author":"V Ficarra","year":"2019","unstructured":"Ficarra V, Mosca A, Rossanese M et al (2019) Is active surveillance an option for metachronous metastatic renal cell carcinoma? Ann Transl Med 7:84. https:\/\/doi.org\/10.21037\/atm.2019.01.08","journal-title":"Ann Transl Med"},{"key":"3632_CR50","doi-asserted-by":"publisher","first-page":"526.e13","DOI":"10.1016\/j.urolonc.2018.08.018","volume":"36","author":"D Bimbatti","year":"2018","unstructured":"Bimbatti D, Ciccarese C, Fantinel E et al (2018) Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. UrolOncolSeminOrigInvestig 36:526.e13-526.e18. https:\/\/doi.org\/10.1016\/j.urolonc.2018.08.018","journal-title":"UrolOncolSeminOrigInvestig"},{"key":"3632_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","volume":"76","author":"L Albiges","year":"2019","unstructured":"Albiges L, Powles T, Staehler M et al (2019) Updated European Association of Urology Guidelines on Renal Cell Carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. EurUrol 76:151\u2013156. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.022","journal-title":"EurUrol"},{"key":"3632_CR52","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.eururo.2016.09.034","volume":"71","author":"U Capitanio","year":"2017","unstructured":"Capitanio U, Larcher A, Dell\u2019Oglio P, Montorsi F (2017) Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol Lancet 2016;17:1317-24: Active surveillance in metastatic renal cell carcinoma: option or exception? EurUrol 71:e139\u2013e140. https:\/\/doi.org\/10.1016\/j.eururo.2016.09.034","journal-title":"EurUrol"},{"key":"3632_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. EurUrol 67:913\u2013924. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.005","journal-title":"EurUrol"},{"issue":"Suppl4","key":"3632_CR54","doi-asserted-by":"publisher","first-page":"S1142","DOI":"10.1016\/annoncannonc325","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Powles T, Burotto M, Bourlon MT, Zurawski B, Ju\u00e1rez VMO, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Barrios CH, Richardet M, Pook D, Tomita Y, Escudier B, Zhang J, Simsek B, Apolo AB, Motzer RJ (2020) Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol 31(Suppl4):S1142\u2013S1215. https:\/\/doi.org\/10.1016\/annoncannonc325","journal-title":"Ann Oncol"},{"key":"3632_CR55","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"3632_CR56","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"3632_CR57","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet LondEngl 393:2404\u20132415. https:\/\/doi.org\/10.1016\/S0140-6736(19)30723-8","journal-title":"Lancet LondEngl"},{"key":"3632_CR58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","volume":"53","author":"N Bhojani","year":"2008","unstructured":"Bhojani N, Jeldres C, Patard J-J et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. EurUrol 53:917\u2013930. https:\/\/doi.org\/10.1016\/j.eururo.2007.11.037","journal-title":"EurUrol"},{"key":"3632_CR59","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s12325-019-01167-2","volume":"37","author":"KM Manz","year":"2020","unstructured":"Manz KM, Fenchel K, Eilers A et al (2020) Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis. AdvTher 37:730\u2013744. https:\/\/doi.org\/10.1007\/s12325-019-01167-2","journal-title":"AdvTher"},{"key":"3632_CR60","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","volume":"16","author":"JA Thompson","year":"2018","unstructured":"Thompson JA (2018) New NCCN Guidelines: recognition and management of immunotherapy-related toxicity. J NatlCompr Cancer Netw JNCCN 16:594\u2013596. https:\/\/doi.org\/10.6004\/jnccn.2018.0047","journal-title":"J NatlCompr Cancer Netw JNCCN"},{"key":"3632_CR61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"3632_CR62","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","volume":"4","author":"AN Shoushtari","year":"2018","unstructured":"Shoushtari AN, Friedman CF, Navid-Azarbaijani P et al (2018) Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 4:98\u2013101. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2391","journal-title":"JAMA Oncol"},{"key":"3632_CR63","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"3632_CR64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T et al (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. https:\/\/doi.org\/10.1186\/s12916-015-0455-8","journal-title":"BMC Med"},{"key":"3632_CR65","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008\u20131019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"3632_CR66","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV et al (2018) Fatal Toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"3632_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70:86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"3632_CR68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40266-019-00644-1","volume":"36","author":"J Esther","year":"2019","unstructured":"Esther J, Hale P, Hahn AW et al (2019) Treatment decisions for metastatic clear cell renal cell carcinoma in older patients: the role of TKIs and immune checkpoint inhibitors. Drugs Aging 36:395\u2013401. https:\/\/doi.org\/10.1007\/s40266-019-00644-1","journal-title":"Drugs Aging"},{"key":"3632_CR69","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J ClinOncol Off J Am SocClinOncol 20:289\u2013296. https:\/\/doi.org\/10.1200\/JCO.2002.20.1.289","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"key":"3632_CR70","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J ClinOncol Off J Am SocClinOncol 17:2530\u20132540. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2530","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"key":"3632_CR71","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DYC Heng","year":"2009","unstructured":"Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J ClinOncol Off J Am SocClinOncol 27:5794\u20135799. https:\/\/doi.org\/10.1200\/JCO.2008.21.4809","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"key":"3632_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DYC Heng","year":"2013","unstructured":"Heng DYC, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141\u2013148. https:\/\/doi.org\/10.1016\/S1470-2045(12)70559-4","journal-title":"Lancet Oncol"},{"key":"3632_CR73","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.2017.35.6_suppl.492","volume":"35","author":"S Yip","year":"2017","unstructured":"Yip S, Wells C, Moreira RB et al (2017) Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. J ClinOncol 35:492\u2013492. https:\/\/doi.org\/10.1200\/JCO.2017.35.6_suppl.492","journal-title":"J ClinOncol"},{"key":"3632_CR74","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.clgc.2016.12.005","volume":"15","author":"SK Pal","year":"2017","unstructured":"Pal SK, Ghate SR, Li N et al (2017) Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER\u2013Medicare Database analysis. ClinGenitourin Cancer 15:e573\u2013e582. https:\/\/doi.org\/10.1016\/j.clgc.2016.12.005","journal-title":"ClinGenitourin Cancer"},{"key":"3632_CR75","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12885-019-5716-z","volume":"19","author":"S Pal","year":"2019","unstructured":"Pal S, Gong J, Mhatre SK et al (2019) Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 19:548. https:\/\/doi.org\/10.1186\/s12885-019-5716-z","journal-title":"BMC Cancer"},{"key":"3632_CR76","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/0959-8049(95)00664-8","volume":"32A","author":"G Buccheri","year":"1990","unstructured":"Buccheri G, Ferrigno D (1990) Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer OxfEngl 32A:1135\u20131141. https:\/\/doi.org\/10.1016\/0959-8049(95)00664-8","journal-title":"Eur J Cancer OxfEngl"},{"key":"3632_CR77","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1200\/JCO.2001.19.4.1147","volume":"19","author":"R Yancik","year":"2001","unstructured":"Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J ClinOncolOff J Am SocClinOncol 19:1147\u20131151. https:\/\/doi.org\/10.1200\/JCO.2001.19.4.1147","journal-title":"J ClinOncolOff J Am SocClinOncol"},{"key":"3632_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.10.032","volume":"126","author":"F Donskov","year":"1990","unstructured":"Donskov F, Motzer RJ, Voog E et al (1990) (2020) Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer OxfEngl 126:1\u201310. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.032","journal-title":"Eur J Cancer OxfEngl"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03632-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T16:03:29Z","timestamp":1716566609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03632-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3632"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03632-6","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jean COURCIER None. Alexandre DE LA TAILLE Intuitive Surgical. Nathalie LASSAU Jazz Pharmaceuticals. Alexandre INGELS Intuitive Surgical, Bristol-Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}